This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS (AVATAR)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2010 by Beijing Anzhen Hospital.
Recruitment status was:  Recruiting
Information provided by:
Beijing Anzhen Hospital Identifier:
First received: November 22, 2010
Last updated: NA
Last verified: July 2010
History: No changes posted
Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI

Condition Intervention Phase
Acute Coronary Syndrome Angioplasty Drug: additional rosuvastatin loading Drug: placebo control Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome

Resource links provided by NLM:

Further study details as provided by Beijing Anzhen Hospital:

Primary Outcome Measures:
  • peri-procedural myocardial damage [ Time Frame: 48 hours after PCI ]

Secondary Outcome Measures:
  • MACE [ Time Frame: 30 days after PCI ]

Estimated Enrollment: 400
Study Start Date: April 2010
Estimated Study Completion Date: May 2011
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rosuvastatin,one month,lipid lowering
additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
Drug: additional rosuvastatin loading
additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
Placebo Comparator: sugar pill, one month
sugar pill is given 18-24hr and 4-6hr before PCI as control
Drug: placebo control
sugar pill is given 18-24hr and 4-6hr before PCI as control


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-75 year old
  • diagnosed as acute coronary syndrome
  • Plan to PCI

Exclusion Criteria:

  • STEMI patient
  • emergency PCI(<2h) for NSTE-ACS
  • History of liver disease and myopathy (ALT/AST>3 x upper limit of normal,CK>5 x upper limit of normal)
  • TG>500mg/dl,CCr<30ml/min
  • inflammatory disease
  • allergic to rosuvastatin
  • nephrotic syndrome,hypothyroidism,systemic lupus erythematosus,myeloma,
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01245803

Contact: Shujjuan Cheng, MD, PhD +861064456995
Contact: Shiying Li, MD +861064456541

China, Beijing
the 28th division, Beijing Anzhen Hospital Recruiting
Beijing, Beijing, China, 100029
Sponsors and Collaborators
Beijing Anzhen Hospital
  More Information

Responsible Party: HYan, BeijingAnzhen Identifier: NCT01245803     History of Changes
Other Study ID Numbers: 6998
Study First Received: November 22, 2010
Last Updated: November 22, 2010

Keywords provided by Beijing Anzhen Hospital:
acute coronary syndrome

Additional relevant MeSH terms:
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on July 28, 2017